-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Researchers from Mount Sinai, New York (October 7, 2021) and the University of California, San Diego, discovered for the first time how mutations affect cells in a process called RNA splicing altered cell culture myelodysplastic syndrome (MDS) and other hematological malignancies and Solid tumors, according to a study published in October, found cancer
Their research found that these mutations produced an alternative version of the protein produced by the GNAS gene
MDS is a rare blood cancer.
"This is the first study to find that the altered protein produced by GNAS is increased in MDS mutant cells, which leads to an activation process that makes cancer cells susceptible to MEK inhibitors
Papapetrou and Dr.
Yeo said: "This work combines the syngeneic model of the disease with the cutting-edge RNAomics, and brings it together on the new target of MDS
These analyses allow the research team to identify high-confidence targets and identify disease drivers
